Melanoma Drug Effective in Trials

Monday, 18 Nov 2013 04:57 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Early data from a small trial of Merck & Co Inc's experimental immunotherapy cancer drug, known as MK-3475, show that about half of advanced melanoma patients treated with the highest dose of the drug experienced tumor shrinkage.

Updated results from the early-stage trial are set to be presented on Monday at the International Congress of the Society for Melanoma Research in Philadelphia.

The antibody drug is part of a new class of compounds designed to block the activity of a receptor on immune cells called programmed death 1, or PD-1. The aim of the drugs is to spur the body's own immune system to attack cancer cells.

Merck said results from 135 patients whose melanoma had stopped responding to earlier rounds of treatment showed that 41 percent had tumor shrinkage - the rate was 51 percent in the high-dose group, and 40 percent for lowest-dose group.

The company estimated overall survival at a year of treatment at 81 percent, but said the trial had not yet reached either a median duration of response or median overall survival.

Serious side effects seen in the trial included fatigue, rash, increased liver enzymes and renal
failure.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Should Prisoners Get Pricy Hepatitis C Drug?

Tuesday, 21 Oct 2014 17:06 PM

When prisoners have hepatitis C, treating them with expensive new antiviral drugs makes fiscal sense despite the hefty p . . .

Binge Drinking Raises Men's Blood Pressure: Study

Tuesday, 21 Oct 2014 16:56 PM

Binge drinking among young adult men may lead to increased blood pressure, according to a new study.
But binge drin . . .

Lack of Sleep Raises Colitis Risk

Tuesday, 21 Oct 2014 16:55 PM

New research shows chronic sleep loss increases the risk of developing ulcerative colitis. . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved